Roche to appeal against preliminary NICE no for Herceptin for metastatic gastric cancer
This article was originally published in Scrip
Executive Summary
Roche says it will appeal against preliminary draft guidance from the National Institute for health and Clinical Excellence (NICE) in England and Wales that declines to recommend Roche's HER2-targeted Herceptin (trastuzumab) for treating metastatic gastric cancer patients on the NHS. NICE says it has doubts over the drug's capacity to extend life.